Cara Therapeutics: Creating the Future of Analgesics and Anti-Inflammatory Drugs

As an emerging biotechnology company, Cara Therapeutics has focused its resources in developing novel medications for diseases associated with pain and inflammation. The company has a product candidate that is currently being studied as treatment for various human maladies.

Founded in 2004 and based in Shelton, Connecticut, Cara Therapeutics has the CR845 as its lead product candidate. This novel medication has completed its phase II of clinical trial for treatment of acute postoperative pain in adult patients. It has also completed its phase I trial for usage in moderate to severe acute and chronic pain. They also have the CR701 which is currently being looked into as a medication for treating inflammatory and neuropathic pain. The chemical entities that the company is developing are designed to target kappa opioid receptors, thereby alleviating pain.

The company is publicly traded on the NASDAQ and trades under the ticker symbol CARA. It continues to do its research to create novel products for future analgesics and anti-inflammatory therapeutics.